"High pill burden has been indicated in noncompliance that can lead to relapse," he told attendees at the meeting. Dr. Sandborn and his team combined efficacy and safety data from 2 randomized, controlled, phase 3 clinical trials. Each SPD476 tablet includes a 1.2-g dose of mesalamine and...
[6]. Although the main focus has been on the treatment of SAM children, children with MAM are also vulnerable, as their condition will progress to SAM if not treated properly. Efforts are being made to eradicate the burden, but, unfortunately, the progress toward achieving the global ...